Evotec and Boehringer Ingelheim extend collaboration

Evotec has extended its collaboration with Boehringer Ingelheim for a further four years. The collaboration, which began in August 2004, has already been extended on two previous occasions.

At the same time, the scope of the collaboration has been extended from CNS, inflammation, cardiometabolic and respiratory diseases also to include oncology targets. Over the next four years Evotec will receive research funding of around b15m plus milestone and royalty payments.

"This extension speaks volumes for the excellent scientific results achieved," said Dr Werner Lanthaler, chief executive of Evotec.